Multiplex PCR for 17 Y-Chromosome Specific Short Tandem Repeats (STR) to Enhance the Reliability of Fetal Sex Determination in Maternal Plasma by Rong, Yuan et al.
Int. J. Mol. Sci. 2012, 13, 5972-5981; doi:10.3390/ijms13055972 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Multiplex PCR for 17 Y-Chromosome Specific Short Tandem 
Repeats (STR) to Enhance the Reliability of Fetal Sex 
Determination in Maternal Plasma 
Yuan Rong 
1, Jiajia Gao 
1, Xinqiang Jiang 
2 and Fang Zheng 
1,* 
1  Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University, Donghu Rd 169,   
Wuchang District, Wuhan 430071, China; E-Mails: whushine@163.com (Y.R.); 
jia1104ab@163.com (J.G.) 
2  Institute of Forensic Science, Zhongnan Hospital of Wuhan University, Donghu Rd 169,   
Wuchang District, Wuhan 430071, China; E-Mail: mephiston@163.com 
*  Author to whom correspondence should be addressed; E-Mail: zhengfang@whu.edu.cn;   
Tel.: +86-27-67813233; Fax: +86-27-67813497. 
Received: 27 March 2012; in revised form: 2 May 2012 / Accepted: 9 May 2012 / 
Published: 16 May 2012 
 
Abstract:  The  aim  of  the  study  was  to  demonstrate  the  influence  of  target  gene  and 
amplification product length on the performance of fetal gender determination systems 
using maternal plasma. A total of 40 pairs of plasma DNA samples from pregnant women 
and genomic DNA samples from maternal blood, amniotic fluid and paternal blood were 
isolated  for  gender  determination  by  amplification  of  the  amelogenin  gene  and  17 
Y-chromosome STR loci, using three different commercial kits. The gender of the fetuses 
was  confirmed  by  cytogenetic  analysis  or  phenotype  at  birth.  Both  the 
AmpFℓSTR-Identifiler  amplification  kit  and  the  Mini-STR  Amplification  kit  for 
amelogenin gene detection were reliable in determining fetal gender (92.0% and 96.0%, 
respectively), but false negatives were present in  both systems. AmpFℓSTR-Yfiler was 
found to be fully reliable as it amplified Y-STR in all cases of pregnancies with male 
fetuses and thus was 100% correct in determining fetal gender. The results demonstrated 
that  multiple  fluorescent  PCR  for  17  Y-STR  loci  was  more  reliable  than  AMELY   
gene  testing  in  fetal  sex  determination  with  maternal  plasma.  We  also  found  that  the   
shorter  amplification  products  could  improve  the  performance  of  fetal  gender 
determination systems. 
OPEN ACCESS Int. J. Mol. Sci. 2012, 13  5973 
 
Keywords:  cell-free  fetal  DNA;  noninvasive  prenatal  diagnosis;  gender  determination; 
Y-chromosome specific STR   
 
1. Introduction 
Prenatal gender determination is used for women at high risk of serious sex-linked genetic disorders. 
Traditionally, this is undertaken by invasive testing such as chorionic villus sampling or amniocentesis, 
both of which carry a small but significant (less than 1%) risk of miscarriage and may be harmful for 
both mother and fetus. The identification of cell-free fetal DNA in 1997 by Dennis Lo in the maternal 
circulation has allowed the development of non-invasive prenatal diagnostic testing [1], which permits 
fetal sex determination without risk to the pregnancy. 
The identification of Y-chromosome specific DNA sequences in maternal plasma is indicative of a 
male fetus. To date, many different Y-chromosome specific DNA sequences have been amplified and 
used to identify male fetuses, including SRY, DYS14, DYS1/DAZ, DYZ3, AMELY, etc. Although results 
are encouraging, diagnostic accuracy varies according to different methods and target genes used, with 
sensitivity and specificity ranging from 90% to 100% [2]. The different techniques used for fetal sex 
determination, such as conventional PCR, nested PCR and real-time PCR, always affect the detection 
performance.  False-negative  results  are  the  major  drawback  with  noninvasive  prenatal  fetal  sex 
determination, simply because there is not enough fetal DNA in  the maternal plasma for a 100% 
successful amplification. To overcome this problem, we adopted a multiple fluorescent PCR technique 
to detect AMELY and 17 Y-STR loci for fetal gender determination.   
The amelogenin gene is a chromosome X/Y homologous gene. There is a 6 bp difference in intron 3 
of  the  amelogenin  gene  between  the  X-linked  amelogenin  (AMELX)  and  the  Y-linked  amelogenin 
(AMELY). Detection of the 6 bp difference may help us evaluate prenatal fetal gender, which has been 
widely used in forensic studies [3]. In our study, we used two different amplification kits to amplify 
AMELY to detect fetal gender; we also used multiple fluorescent PCR to observe the influence of the 
product size of the target gene on the detection performance. 
Y-STR  are  short  tandem  repeats  (STR)  that  occur  specifically  on  the  Y-chromosome,  and  are 
therefore unique to the male fetus. The use of Y-STR in forensic evidence allows for the genetic 
identification of the male component in a mixture of male and female DNA components. Further, even 
if the amount of female DNA incorporated into the PCR reaction is 100 times more than the amount of 
male DNA, the female DNA will not interfere with the interpretation of the Y-STR profile [4]. Because 
of this, the maternal plasma mixture of low copy fetal DNA and high background maternal DNA 
allows Y-STR genotyping of fetal DNA without interference by maternal background DNA. Therefore, 
Y-STR typing has the potential to become a useful tool in sex determination using maternal plasma. 
In our study, two different amplification systems, the AMELY gene test and 17 multiple Y-STR test, 
were  used  to  determine  fetal  gender.  In  the  AMELY  gene  test  system,  we  used  two  kits  for 
amplification of AMELY products of two lengths—106–112 bp for the AmpFℓSTR-Identifiler kit and 
77–83 bp for the Mini-STR kit—to demonstrate the influence of amplification product length on the 
performance of fetal gender detection with maternal plasma. Int. J. Mol. Sci. 2012, 13  5974 
 
2. Results and Discussions 
2.1. Fetal Gender Confirmation 
The gender of fetuses was confirmed by cytogenetic analysis of amniotic fluid or phenotype at birth. 
In the 40 samples collected, 25 pregnant women had a male fetus. 
2.2. Fetal Gender Determination by AMELY Tests   
Using the AmpFℓSTR-Identifiler Kit, we were able to successfully amplify Y-chromosome specific 
AMELY  in  23  out  of  25  maternal  plasma  samples  from  mothers  bearing  male  fetuses.  Using  the 
Mini-STR  amplification  kit,  AMELY  was  successfully  amplified  in  24  out  of  25  maternal  plasma 
samples with male fetuses (as shown in Table 1). There were no cases of falsely amplified AMELY 
when  both  the  AmpFℓSTR-Identifiler  kit  and  Mini-STR  kit  were  used  on  samples  from  mothers 
bearing  female  fetuses.  When  the  genotyping  results  obtained  from  maternal  plasma,  maternal 
blood-cell portion and amniotic fluid were compared, AMELY was the only locus that was reliably 
amplified; autosomal fetal STR loci originating from the father (as shown in Figure 1) were amplified 
only sporadically due to the allelic suppression. 
Table 1. Fetal gender determination by maternal plasma samples with male fetuses using 
two different target regions (AMELY test and Y-STR detection). 
Sample 
No. 
Gestational 
age (weeks) 
AMELY Test  Multiple Y-STR Amplification 
AmpFℓSTR 
Identifiler Kit 
AGCU 
Mini-STR Kit 
Amplified 
Y-STR Loci 
Matching to   
Paternal Blood 
1  15  XY  XY  5  5 
2  16  XY  XY  7  7 
3  24  XY  XY  11  11 
4  28  XX  XY  6  6 
5  26  XY  XY  9  9 
6  28  XY  XY  10  10 
7  27  XY  XY  10  10 
8  36  XY  XY  8  8 
9  35  XY  XY  8  8 
10  28  XY  XY  10  10 
11  16  XX  XY  7  7 
12  36  XY  XY  10  10 
13  23  XY  XY  8  8 
14  15  XY  XX  6  6 
15  16  XY  XY  12  12 
16  12  XY  XY  5  5 
17  13  XY  XY  6  6 
18  17  XY  XY  8  8 
19  24  XY  XY  5  5 
20  14  XY  XY  6  6 
21  22  XY  XY  8  8 
22  20  XY  XY  8  8 
23  18  XY  XY  7  7 
24  22  XY  XY  9  9 
25  15  XY  XY  7  7 Int. J. Mol. Sci. 2012, 13  5975 
 
Figure 1. Genotype of AMELY and autosomal STR from maternal plasma with a male 
fetus using the AmpFℓSTR-Identifiler kit (left) and AGCU Mini-STR Amplification kit 
(right) when compared with maternal blood and amniotic fluid. A third, smaller ―paternal‖ 
allele is indicated by the arrow, corresponding to the fetal allele that is inherited from   
the father. 
Maternal Blood (Maternal Genotype) 
   
Maternal Plasma (Mixed) 
   
Amniotic Fluid (Fetal Genotype) 
   
2.3. Fetal Gender Determination by Y-STR Tests Using AmpFℓSTR-Yfiler Kit 
On  the  basis  of  the  presence  of  detected  Y-STR  alleles  and  the  value  of  allelic  peak  height, 
AmpFℓSTR-Yfiler Kit was found to be fully reliable as it amplified Y-STR in all 25 cases of maternal 
plasma from pregnant women with male fetuses, while none of these 17 Y-STR loci was detected in   
15 plasma samples  from  pregnant  women carrying female fetuses, and was  thus  100% correct  in 
determining fetal gender. All 25 cases of male fetuses were successfully amplified between five and 
twelve fetal loci (Table 1, Figure 1). An average of 7.8 Y-STR loci was detected. In addition, the 
genotype of all the amplified Y-STR derived from the maternal plasma matched the alleles amplified 
from the corresponding amniotic fluid and paternal blood, thus further supporting the fact that the 
amplified fragments originated from the Y-chromosome, and not from nonspecific amplification of 
another DNA fragment (as shown in Table 2). Int. J. Mol. Sci. 2012, 13  5976 
 
Figure 2. Y-STR genotyping of DNA from maternal plasma with a male fetus (16 weeks of 
pregnancy). 12 out of 17 STR loci were successfully amplified. 
 
Table 2. Comparison of polymorphic Y-chromosome STR loci between father and fetus. 
The genotype of a fetus from maternal plasma was shown in a tabular form and compared 
to the genotype obtained from paternal blood. All Y-STR alleles amplified from maternal 
plasma  were  identical  to  paternal  alleles,  which  further  confirmed  that  they  indeed 
originated from the fetal Y chromosome. 
  DYS456  DYS389 I  DYS390  DYS389 II  DYS458  DYS19  DYS385a/b  DYS393 
maternal plasma  16  12  23  29  15  15  14,14  13 
paternal blood  16  12  23  29  15  15  14,14  13 
  DYS391  DYS439  DYS635  DYS392  Y_GATA_H4  DYS437  DYS438  DYS448 
maternal plasma  10  11  20  14  11  14  10  18 
paternal blood  10  11  -  -  11  14  -  - 
2.4. Discussion 
In the noninvasive prenatal fetal  gender determination  from  maternal  plasma, there  are several 
factors which will affect the detection performance, including sample handling and DNA extraction 
efficiency, amplification techniques and the gestational age [2]. 
In this study, we demonstrated the effect of both amplification product size and the different target 
genes on fetal gender determination. The principle of the commercially available forensic sex tests is Int. J. Mol. Sci. 2012, 13  5977 
 
based on the polymorphism present on the two homologous copies of the amelogenin gene on the X 
and Y chromosomes (AMELX/AMELY). The primer pairs used for genotyping are those described by 
Sullivan et al., detecting a 6 bp deletion/insertion on the X/Y chromosomes [5]. The relatively short 
amplicon length of 106 and 112 bp, respectively, is usually sufficient for routine DNA typing. However, 
with highly degraded DNA, even this stretch might be too long for adequate analysis. Fetal DNA 
molecules in the maternal plasma are generally shorter than maternal DNA molecules, less than 150 bp 
in length [6]. On the basis of the characteristics of circulatory fetal DNA in maternal plasma, we used a 
Mini-STR amplification kit in which all amplified allele sizes were less than 250 bp in length, to detect 
the AMEL gene with even shorter amplicons of 77–83 bp, to study the influence of the allele size on   
the  detection  performance.  According  to  the  results  of  our  study,  both  the  AmpFℓSTR-Identifiler 
amplification kit and Mini-STR Amplification kit were reliable in amplifying the AMELY gene to 
determine  fetal  gender  (92.0%  and  96.0%,  respectively).  There  was  no  statistically  significant 
difference between the two kits. The single difference of incorrect samples between them may be a 
result of the biochemical character of circulatory fetal DNA. It was showed that the STR loci with 
shorter allele size had a greater chance of being amplified in both the fetal autosomal STR detecting 
system and the Y-STR detecting system than the STR loci with longer allele size. The autosomal STR loci 
were amplified only sporadically, most probably because of suppressed primer binding due to the presence 
of high-background maternal DNA. For the genotyping of Y-STR from maternal plasma, the STR loci 
with shorter allele sizes, such as DYS456, with an allele size ranging from 100–127 bp, and DYS393 
(106–144  bp),  were  amplified  in  23  and  20  out  of  25  maternal  plasma  samples  with  male  fetus, 
respectively,  while  the  STR  loci  with  longer  allele  sizes,  such  as  DYS392  (286–335  bp)  and   
DYS635 (242–274 bp), were only amplified in 2 and 1 out of 25 maternal plasma samples with male   
fetus, respectively. 
Although fetal sex determination with both systems of detecting the AMELY gene was reliable, 
false-negative results were still present. Suppression of minor alleles is a common complication in the 
analysis of low-copy DNA samples. It has been reported that, on average, 3–6% of cell-free DNA in 
maternal plasma can be of fetal origin [7]. A higher fraction (around 10–20%) of fetal DNA has been 
found in maternal plasma using microfluidics digital PCR [8].   
The  absence  of  amplification  of  AMELY  in  these  cases  could  have  been  a  consequence  of 
inadequate quantity of fetal DNA and the corresponding allelic suppression, but this was probably not 
the only reason, since different methods gave false negatives in different individuals. Individual false 
negative samples are listed in Table 1. Even some samples with good results by Y-STR amplification 
were  falsely  negative  by  AMELY  detection,  which  strongly  supports  the  hypothesis  that  falsely 
negative results may be caused by some type of variability in primer binding regions; inadequate 
amplification efficiency of different primers or the Y-chromosome micro-deletion were actually not 
very common but existed in some cases.   
To eliminate these problems mentioned above, the AmpFℓSTR-Yfiler system was used to amplify 
17 STR loci located on the Y-chromosome in parallel. Since primers from this system do not bind to 
maternal background DNA, the allelic suppression could be avoided and significantly better results 
were obtained. Between five and twelve fetal loci were successfully amplified from plasma of mothers 
bearing male fetuses (Table 1, Figure 2). All amplified alleles matched to alleles detected in samples of 
paternal blood, excluding the possibility of falsely positive results caused by DNA contamination. Int. J. Mol. Sci. 2012, 13  5978 
 
Furthermore,  the  method  that  the  17  Y-STR  multiplex  amplification  kit  utilizes  in  fetal  gender 
determination can also avoid the false-negatives resulting from individual variability in primer binding 
region and Y-chromosome micro-deletion. Although these problems do not occur frequently, they may 
be  the  reason  for  the  false-negative  results  when  using  the  single  Y-chromosome  specific  gene 
detection for fetal gender determination such as the SRY or AMELY gene [9]. 
The multiple Y-STR loci amplification can overcome this problem by amplifying two or more 
Y-chromosome specific target  regions in parallel, which can be complementary to  each other and 
improve the detection accuracy. In addition, Y-STR testing may be useful in some cases of fetal sex 
chromosome  abnormality.  The  male  fetuses  with  Supermale  Syndrome  (XYY)  may  cause  the 
appearance of two peaks at one or more Y-STR loci while other sex chromosome aneuploidy diseases 
such as XXY, XO, XXX and mosaic conditions cannot be identified by Y-STR testing because fetal 
sex chromosome dosage cannot be accurately evaluated with maternal plasma by this method. 
Our results need to be confirmed by further studies in a larger clinical cohort and at an earlier 
gestational age because larger clinical trials reporting the sensitivity and specificity of this diagnostic 
procedure are unavailable. Moreover, as an ethical issue, this method might also be misapplied in 
prenatal sex selection. Therefore, there should be careful consideration about the use of this analytical 
tool in clinical situations. Note should be taken that fetal sex determination for non-medical reasons is 
unethical and prohibited in some countries. 
3. Experimental Section 
3.1. Participant Recruitment and Sample Collection   
This study was performed in accordance with the Declaration of Helsinki and approved by the local 
ethical committee of Zhongnan Hospital of Wuhan University. Peripheral blood samples (n = 40) were 
collected  from  pregnant  women  who  had  a  gestational  age  of  12–36  weeks.  The  corresponding 
amniotic fluid and blood samples from fathers were also collected. Informed consent was obtained 
from all studied individuals.   
3.2. Sample Processing and DNA Extraction 
Maternal peripheral blood samples (4 mL) were drawn and collected in tubes containing EDTA as 
anticoagulant,  and  the  blood  samples  were  stored  at  4  ° C  before  centrifugation.  The  blood 
centrifugation  was  performed  within  6  h  after  collection.  The  blood  samples  were  separated  into 
plasma and blood cells by centrifuging at 1600×  g for 10 min at 4 ° C. The plasma portion and the 
blood-cell portion were re-centrifuged at 16,000×  g for 10 min at 4 ° C to remove any residual blood 
cells or plasma and were stored at −80 °C before further processing.   
Cell-free DNA was extracted from 2.0 mL of plasma with the QIAamp Ultrasens Virus Kit (Qiagen, 
Germany) according to the manufacturer’s protocol. 
DNA  from  the  maternal  blood-cell  portion,  paternal  peripheral  blood  and  amniotic  fluid  were 
extracted by chelex-100 method [10]. Int. J. Mol. Sci. 2012, 13  5979 
 
3.3. Amplification Using Applied Biosystems AmpFℓSTR-Identifiler Kit 
DNA from maternal plasma, maternal blood-cell portion and amniotic fluid were amplified using 
AmpFℓSTR-Identifiler Kit (Applied Biosystems, Foster City, CA). PCR reaction was performed in a 
final volume of 10 μL containing 4 μL AmpFℓSTR PCR reaction mix, 2 μL AmpFℓSTR-Identifiler 
primer  set,  0.33  μL  AmpliTaq  Gold  DNA  Polymerase(5  U/μL)  and  3.67  μL  template  DNA.  The 
thermal profile was 95 ° C for 11 min, followed by 28 cycles of 94 ° C for 60 s, 59 ° C for 60 s, 72 ° C 
for 60 s, and 60 ° C for 45 min. The AmpFℓSTR-Identifiler Kit amplifies 15 autosomal STR loci plus 
the amelogenin gene. These loci include: CSF1PO, D13S317, D16S539, D18S51, D21S11, D3S1358, 
D5S818, D7S820, D8S1179, FGA, TH01, TPOX, vWA, D2S1338 and D19S433.   
3.4. Amplification Using AGCU Mini-STR Amplification Kit 
DNA from maternal plasma, maternal blood-cell portion and amniotic fluid were amplified using 
Mini-STR Amplification kit (AGCU, China). PCR reaction was performed in a final volume of 10 μL 
containing  4 μL  AGCU  PCR  Reaction  Mix, 2 μL Mini  Primer  Set,  0.2 μL  Hot-start G-taq DNA 
Polymerase (5 U/μL) and 3.8 μL template DNA. The thermal profile was 95 ° C for 11 min, 10 cycles 
of 94 ° C for 60 s, 62 ° C for 60 s, 72 ° C for 60 s, followed by 20 cycles of 90 ° C for 60 s, 60 ° C for   
60 s, 72 ° C for 60 s, and 60 ° C for 45 min. The Mini-STR Amplification Kit amplifies 8 autosomal 
STR  loci  and  the  amelogenin  gene.  These  loci  include:  Penta  E,  D21S391,  D6S1043,  D2S1338, 
CSF1PO, Penta D, D19S253. 
3.5. Amplification Using AmpFℓSTR-Yfiler Kit 
DNA  from  maternal  plasma,  paternal  blood-cell  and  amniotic  fluid  were  amplified  using 
AmpFℓSTR-Yfiler Kit (Applied Biosystems, Foster City, CA, USA). PCR reaction was performed in a 
final  volume of 10 μL  containing 4 μL  AmpFℓSTR PCR  Reaction  Mix, 2 μL AmpFℓSTR-Yfiler 
Primer  Set,  0.33 μL  AmpliTaq  Gold  DNA  Polymerase(5  U/μL)  and  3.67  μL  template  DNA.  The 
thermal profile was 95 ° C for 11 min, followed by 30 cycles of 94 ° C for 60 s, 61 ° C for 60 s, 72 ° C 
for 60 s, and 60 ° C for 80 min. The AmpFℓSTR-Yfiler PCR Amplification Kit amplifies 17 loci: 
DYS456, DYS389I, DYS390, DYS389II, DYS458, DYS19, DYS385a/b, DYS393, DYS391, DYS439, 
DYS635, DYS392, Y_GATA_H4, DYS437, DYS438, and DYS448.   
3.6. Analysis of Amplified Products 
These amplified products were separated and detected by capillary electrophoresis on the ABI 3130 
Genetic  Analyzer  using  the  GeneMapper  ID  v3.2  software  for  analysis  with  the  corresponding   
analysis method. 
4. Conclusion 
In summary, the shorter length of amplification products could improve the performance of fetal 
gender determination. Multiple fluorescent PCR for 17 Y-chromosome STR loci was more reliable in 
prenatal sex determination than AMELY testing, which could both enable the comparison of Y-STR Int. J. Mol. Sci. 2012, 13  5980 
 
genotype between father and child to avoid the false positive results, and also amplify multiple Y-STR 
loci simultaneously to avoid the false negative results.   
Acknowledgements 
This work was supported by grants from the Science and Technology Research Plan of Wuhan City 
(No.201060938364-01),  Research  Funds  of  Zhongnan  Hospital  (No.201003)  and  the  Fundamental 
Research Fund for the Central Universities (No.201130302020002). We thank the pregnant women 
and their husbands for providing us samples for our study. We also thank Hailong Zhang and Susan 
Peirce, from Emory University School of Medicine, for their help with the manuscript’s editing of the 
English language and style. 
Conflict of Interest 
The authors declare no conflict of interest. 
References 
1.  Lo, Y.M.D.; Corbetta, N.; Chamberlain, P.F.; Rai, V.; Sargent, I.L.; Redman, C.W.G.; Wainscoat, J.S. 
Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350, 485–487. 
2.  Devaney, S.A.; Palomaki, G.E.; Scott, J.A.; Bianchi, D.W. Noninvasive fetal sex determination 
using cell-free fetal DNA: A systematic review and meta-analysis. J. Am. Med. Assoc. 2011, 306, 
627–636. 
3.  Mannucci,  A.;  Sullivan,  K.M.;  Ivanov,  P.L.;  Gill,  P.  Forensic  application  of  a  rapid  and 
quantitative  DNA  sex  test  by  amplification  of  the  X–Y  homologous  gene  amelogenin.   
Int. J. Legal Med. 1994, 106, 190–193. 
4.  Johnson, C.L.; Warren, J.H.; Giles, R.C.; Staub, R.W. Validation and uses of a Y-chromosome 
STR 10-plex for forensic and paternity laboratories. J. Forensic Sci. 2003, 48, 1260–1268. 
5.  Sullivan, K.M.; Mannucci, A.; Kimpton, C.P.; Gill, P. A rapid and quantitative DNA sex test: 
Fluorescence-based PCR analysis of X–Y homologous gene amelogenin. BioTechniques 1993, 15, 
636–638, 640–631. 
6.  Fan,  H.C.;  Blumenfeld,  Y.J.;  Chitkara,  U.;  Hudgins,  L.;  Quake,  S.R.  Analysis  of  the  size 
distributions of fetal and maternal cell-free DNA by paired-end sequencing. Clin. Chem. 2010, 56, 
1279–1286. 
7.  Birch, L.; English, C.A.; O’Donoghue, K.; Barigye, O.; Fisk, N.M.; Keer, J.T. Accurate and robust 
quantification  of  circulating  fetal  and  total  DNA  in  maternal  plasma  from  5  to  41  weeks  of 
gestation. Clin. Chem. 2005, 51, 312–320. 
8.  Lun,  F.M.F.;  Chiu,  R.W.K.;  Allen  Chan,  K.C.;  Yeung  Leung,  T.;  Kin  Lau,  T.;  Lo,  Y.M.D. 
Microfluidics  digital  PCR  reveals  a  Higher  than  expected  fraction  of  fetal  DNA  in  maternal 
plasma. Clin. Chem. 2008, 54, 1664–1672. 
9.  Steinlechner, M.; Berger, B.; Niederstatter, H.; Parson, W. Rare failures in the amelogenin sex test. 
Int. J. Legal Med. 2002, 116, 117–120. Int. J. Mol. Sci. 2012, 13  5981 
 
10.  Walsh, P.S.; Metzger, D.A.; Higuchi, R. Chelex 100 as a medium for simple extraction of DNA 
for PCR-based typing from forensic material. BioTechniques 1991, 10, 506–513. 
© 2012  by the authors; licensee MDPI, Basel, Switzerland. This  article is  an open access  article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 